{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Chapter 3: Dyslipidemia in Patients with Type 2 Diabetes: Special Challenges - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"WBEItdZRi4\"><a href=\"https:\/\/themedicalxchange.com\/en\/review\/strategies-beyond-statins-for-control-of-dyslipi-3\/\">Chapter 3: Dyslipidemia in Patients with Type 2 Diabetes: Special Challenges<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/review\/strategies-beyond-statins-for-control-of-dyslipi-3\/embed\/#?secret=WBEItdZRi4\" width=\"600\" height=\"338\" title=\"&#8220;Chapter 3: Dyslipidemia in Patients with Type 2 Diabetes: Special Challenges&#8221; &#8212; The Medical Xchange\" data-secret=\"WBEItdZRi4\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2013\/01\/Dyslipidemia_2504_Woo_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Cardiovascular (CV) disease accounts for a large proportion of the excess and premature mortality related to type 2 diabetes mellitus (DM2). In relation to age-matched individuals, people with DM2 are two to three times more likely to have a CV event than age-matched people without diabetes.(1) According to data from the Canadian Diabetes Association (CDA), approximately 80% of patients with DM2 die of CV disease or stroke, which is a rate that is 2 to 4 times greater than in patients without diabetes.(2) Optimal protection from CV events depends on tight control of the major risk factors that are commonly identified in patients with DM2, including hyperlipidemia and hypertension in addition to hyperglycemia.     Of these risk factors, hyperlipidemia deserves particular attention. Data from several studies, including UKPDS, support the premise that tight control of lipids, relative to tight control of other risk factors, provides the greatest relative protection against CV events.(3) In the STENO-2 trial, there was a 57% relative reduction in CV events observed among those reaching treatment goals for lipids, blood pressure, and blood glucose relative to those who did not,(4)but the authors reported that reaching lipid targets may have provided the greatest relative contribution to risk reduction."}